Cargando…
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
BACKGROUND: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122789/ https://www.ncbi.nlm.nih.gov/pubmed/35611270 http://dx.doi.org/10.1093/noajnl/vdac040 |
_version_ | 1784711419231469568 |
---|---|
author | de Groot, John F Kim, Albert H Prabhu, Sujit Rao, Ganesh Laxton, Adrian W Fecci, Peter E O’Brien, Barbara J Sloan, Andrew Chiang, Veronica Tatter, Stephen B Mohammadi, Alireza M Placantonakis, Dimitris G Strowd, Roy E Chen, Clark Hadjipanayis, Constantinos Khasraw, Mustafa Sun, David Piccioni, David Sinicrope, Kaylyn D Campian, Jian L Kurz, Sylvia C Williams, Brian Smith, Kris Tovar-Spinoza, Zulma Leuthardt, Eric C |
author_facet | de Groot, John F Kim, Albert H Prabhu, Sujit Rao, Ganesh Laxton, Adrian W Fecci, Peter E O’Brien, Barbara J Sloan, Andrew Chiang, Veronica Tatter, Stephen B Mohammadi, Alireza M Placantonakis, Dimitris G Strowd, Roy E Chen, Clark Hadjipanayis, Constantinos Khasraw, Mustafa Sun, David Piccioni, David Sinicrope, Kaylyn D Campian, Jian L Kurz, Sylvia C Williams, Brian Smith, Kris Tovar-Spinoza, Zulma Leuthardt, Eric C |
author_sort | de Groot, John F |
collection | PubMed |
description | BACKGROUND: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. METHODS: Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. RESULTS: A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume <3 cc. CONCLUSIONS: Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT. |
format | Online Article Text |
id | pubmed-9122789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91227892022-05-23 Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma de Groot, John F Kim, Albert H Prabhu, Sujit Rao, Ganesh Laxton, Adrian W Fecci, Peter E O’Brien, Barbara J Sloan, Andrew Chiang, Veronica Tatter, Stephen B Mohammadi, Alireza M Placantonakis, Dimitris G Strowd, Roy E Chen, Clark Hadjipanayis, Constantinos Khasraw, Mustafa Sun, David Piccioni, David Sinicrope, Kaylyn D Campian, Jian L Kurz, Sylvia C Williams, Brian Smith, Kris Tovar-Spinoza, Zulma Leuthardt, Eric C Neurooncol Adv Clinical Investigations BACKGROUND: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. METHODS: Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. RESULTS: A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume <3 cc. CONCLUSIONS: Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT. Oxford University Press 2022-04-06 /pmc/articles/PMC9122789/ /pubmed/35611270 http://dx.doi.org/10.1093/noajnl/vdac040 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Investigations de Groot, John F Kim, Albert H Prabhu, Sujit Rao, Ganesh Laxton, Adrian W Fecci, Peter E O’Brien, Barbara J Sloan, Andrew Chiang, Veronica Tatter, Stephen B Mohammadi, Alireza M Placantonakis, Dimitris G Strowd, Roy E Chen, Clark Hadjipanayis, Constantinos Khasraw, Mustafa Sun, David Piccioni, David Sinicrope, Kaylyn D Campian, Jian L Kurz, Sylvia C Williams, Brian Smith, Kris Tovar-Spinoza, Zulma Leuthardt, Eric C Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma |
title | Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma |
title_full | Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma |
title_fullStr | Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma |
title_full_unstemmed | Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma |
title_short | Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma |
title_sort | efficacy of laser interstitial thermal therapy (litt) for newly diagnosed and recurrent idh wild-type glioblastoma |
topic | Clinical Investigations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122789/ https://www.ncbi.nlm.nih.gov/pubmed/35611270 http://dx.doi.org/10.1093/noajnl/vdac040 |
work_keys_str_mv | AT degrootjohnf efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT kimalberth efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT prabhusujit efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT raoganesh efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT laxtonadrianw efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT feccipetere efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT obrienbarbaraj efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT sloanandrew efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT chiangveronica efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT tatterstephenb efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT mohammadialirezam efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT placantonakisdimitrisg efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT strowdroye efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT chenclark efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT hadjipanayisconstantinos efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT khasrawmustafa efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT sundavid efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT piccionidavid efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT sinicropekaylynd efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT campianjianl efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT kurzsylviac efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT williamsbrian efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT smithkris efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT tovarspinozazulma efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma AT leuthardtericc efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma |